Abstract Search

ea0070aep528 | Endocrine-related Cancer | ECE2020

Sarcopenia can predict response to therapy in NSCLC patients treated with PD-1 inhibitors: A longitudinal prospective study.

Tenuta Marta , Sbardella Emilia , Pandozzi Carla , Gelibter Alain J. , Sirgiovanni Grazia , Giannetta Elisa , Pozza Carlotta , Lenzi Andrea , Isidori Andrea

Introduction: Immune checkpoint inhibitors (ICI) show promising efficacy in the treatment of a wide range of advanced cancers, butlong-term response is currently limited to a subset of patients. Sarcopenia is a condition characterized by loss of skeletal muscle mass and decreased muscle function which occurs in approximately 50% of advanced cancer patients,related to malnutrition, inflammation, and treatments.Objective: The aim of this prospective o...

0 shares

ea0063gp185 | Benign Thyroid Disorders | ECE2019

Thyroid-related adverse events in patients treated with Nivolumab and Pembrolizumab

Sbardella Emilia , Tenuta Marta , Sirgiovanni Grazia , Pozza Carlotta , Gianfrilli Daniele , Mazzotta Paola , Pandozzi Carla , Cortesi Enrico , Lenzi Andrea , Gelibter Alain J , Isidori Andrea M

Introduction: Immune-Checkpoint Inhibitors (ICI) are frequently associated with thyroid-related adverse events (AE). Several studies analyzed thyroid disfunctions during ICI therapy, but many aspects remain to be characterized, especially for the most recent anti-PD-1 drugs. The aim of this study is to determine incidence and characteristics of PD-1 inhibitors associated thyroid dysfunction.Methods: We retrospectively analyzed data of patients with advan...

0 shares

Endocrine Abstracts

Sarcopenia can predict response to therapy in NSCLC patients treated with PD-1 inhibitors: A longitudinal prospective study.

Thyroid-related adverse events in patients treated with Nivolumab and Pembrolizumab

BiosciAbstracts